TALA-125

TALA-125 is a bispecific antibody currently in Phase 1 clinical development by Talawar Therapeutics for the treatment of atopic dermatitis, other dermatologic conditions, and respiratory diseases. The molecule is engineered to simultaneously target and neutralize two key pro-inflammatory cytokines: Interleukin-13 (IL-13) and Interleukin-18 (IL-18). IL-13 is a central mediator of Type 2 (Th2) immune responses, playing a critical role in the pathogenesis of allergic diseases such as atopic dermatitis and asthma by driving skin barrier dysfunction and airway hyperresponsiveness. IL-18 is a member of the IL-1 cytokine family that promotes both Th1 and Th2 responses and is associated with chronic inflammatory and autoimmune conditions. By dual-targeting these pathways, TALA-125 is intended to provide a more comprehensive anti-inflammatory effect than single-target agents, potentially offering improved therapeutic outcomes for patients with complex inflammatory profiles.

Other names

TALA-125TALA125TALA 125